ASH 2021 | Updated results from the BRUIN study: pirtobrutinib in the treatment of MCL
In this video, Michael Wang, MD, University of Texas MD Anderson Cancer Center, Houston, TX, highlights some results from the Phase I/II BRUIN study (NCT03740529) investigating the use of pirtobrutinib, a next generation non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, in previously untreated mantle cell lymphoma (MCL). Dr Wang discusses the patient cohort in this study, as well as the response rates observed, and compares this to covalent BTK inhibitors, including ibrutinib, acalabrutinib, and zanubrutinib. Dr Wang concludes by highlighting the safety profile of pirtobrutinib, and the impact that this drug may have on the future treatment of BTK-resistant patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
Disclosures
Juno: Consultancy, Research Funding; Miltenyi Biomedicine GmbH: Consultancy, Honoraria; Lilly: Research Funding; Moffit Cancer Center: Honoraria; Newbridge Pharmaceuticals: Honoraria; VelosBio: Consultancy, Research Funding; OMI: Honoraria; BGICS: Honoraria; Mumbai Hematology Group: Honoraria; BioInvent: Research Funding; CStone: Consultancy; Hebei Cancer Prevention Federation: Honoraria; Celgene: Research Funding; Oncternal: Consultancy, Research Funding; Molecular Templates: Research Funding; Epizyme: Consultancy, Honoraria; InnoCare: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Clinical Care Options: Honoraria; AstraZeneca: Consultancy, Honoraria, Research Funding; Chinese Medical Association: Honoraria; Scripps: Honoraria; Imedex: Honoraria; Physicians Education Resources (PER): Honoraria; The First Afflicted Hospital of Zhejiang University: Honoraria; DTRM Biopharma (Cayman) Limited: Consultancy; Dava Oncology: Honoraria; Genentech: Consultancy; Janssen: Consultancy, Honoraria, Research Funding; Anticancer Association: Honoraria; BeiGene: Consultancy, Honoraria, Research Funding; CAHON: Honoraria; Kite Pharma: Consultancy, Honoraria, Research Funding; Bayer Healthcare: Consultancy; Loxo Oncology: Consultancy, Research Funding; Acerta Pharma: Consultancy, Honoraria, Research Funding.
